Company ProfilePremium

Nexalis Therapeutics Ltd (formerly Lifespot Health Ltd)

Company Profile Analysis

Ticker: NX1.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Nexalis Therapeutics Ltd - Company showcase

Year Founded & Workforce

2016

Nexalis Therapeutics Ltd logo

Nexalis Therapeutics Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Nexalis Therapeutics Ltd Overview

Nexalis Therapeutics is a Melbourne-based, micro-capitalisation, clinical-stage drug developer whose corporate shell traces back to Lifespot Health, a medical diagnostics and remote-monitoring company that pivoted into medicinal cannabis inhalation devices in 2020–2021 and then into regulated drug development. The company now pursues US FDA approval of three reformulated, previously approved molecules via the 505(b)(2) pathway: IRX-211 (inhaled synthetic THC/dronabinol in a pressurised metered-dose inhaler) for breakthrough cancer pain; IRX-616a (inhaled cannabidiol) for acute panic disorder; and SRX-25 (oral esketamine plus a CYP450 inhibitor) for treatment-resistant depression. Its strategic logic is capital-light reformulation of known actives with rapid onset and better access. However, as of October 2026 the company is in acute financial distress: its A$52.3M debt facility was cancelled in May 2026, a replacement facility collapsed in July 2026, clinical work is suspended, it carries net liabilities of A$1.86M, and its auditor has flagged material going-concern uncertainty.


Company's own description

In its latest filings (Half-Year Report to 30 June 2026; ASX boilerplate from 2026 announcements), the company describes itself as an Australian clinical-stage drug development company developing rapid-onset therapies for unmet needs in pain management and mental health, with an overarching goal of US FDA approval via cost-effective regulatory pathways such as 505(b)(2). The stated principal activity in the 1H2026 Directors' Report is the development of registrable inhaled drugs intended to give fast relief to sufferers of pain and anxiety-related illnesses. The February 2026 rebrand was explained as reflecting a shift beyond inhaled therapies following the addition of the SRX-25 oral program, positioning the company as a diversified clinical-stage developer.

Independent characterisation

Nexalis is a pre-revenue, single-segment, virtual biotech. It owns no manufacturing, no laboratories and has negligible fixed assets (property, plant and equipment of A$12,677 at 30 June 2026). Its value chain position is the "asset sponsor" layer: it holds intellectual property (method-of-use and device-enabled delivery claims, plus a filed international patent application) and contracts out formulation, manufacturing, trial management and site work. The principal outsourced partner is iNGENū CRO Pty Ltd, an entity related to CEO and Executive Director Darryl Davies, which accounted for A$906,712 of the A$1,275,757 product development expenditure in 1H2026 and is owed A$2,125,952 at 30 June 2026.

Business model and revenue model

Revenue categoryCurrent contributionNotes
Product salesNil since FY2022Historic Medihale device/pod sales: A$167,301 in FY2021; minimal in FY2022; discontinued thereafter
ServicesNilHistoric BodyTel telehealth/remote-monitoring services pre-2021
SubscriptionNilMedihale was supplied to patients via clinic prescriptions under the TGA Special Access Scheme (2021)
Licensing / royaltiesNil to dateIntended future model: partner or out-license Phase 3-ready assets
Government incentivesPrincipal "income"R&D Tax Incentive refundable offset: A$761,958 recognised FY2025 (prelim; ~A$986k post-audit, see Section 6), A$630,103 in 1H2026

The intended monetisation route, as stated in funding announcements, is to reach "Phase 3-ready" status for each asset and then realise value through partnering, licensing or trade sale, with lender options structured to vest in tranches when each program becomes Phase 3 ready.

Customer types and end-markets

End-marketTarget patientsPrescriber / payer channel (intended)
Breakthrough cancer pain (BTcP)Opioid-tolerant cancer patients with episodic pain flaresOncology and palliative care; US/EU/AU payers
Panic disorder (PD)Patients experiencing acute panic and anxiety episodesPsychiatry, primary care
Treatment-resistant depression (TRD)Adults failing two or more antidepressantsPsychiatry; aims for home dosing vs clinic-supervised Spravato

Strategy

Stated strategy (themes from FY2025/1H2026 filings and Feb 2026 Clinical Development Outlook)

  1. Pursue New Drug Approvals with the US FDA as quickly and cost-effectively as possible using the 505(b)(2) pathway, leveraging existing safety data for known molecules.

  2. Target indications where current options are mismatched or carry dependency concerns (fentanyl-based BTcP products; benzodiazepines for panic; supervised intranasal esketamine for TRD).

  3. Use non-dilutive, clinical-trial-specific debt funding (with option-based upside to lenders vesting at Phase 3 readiness) instead of equity.

  4. Develop assets to Phase 3 readiness and then partner.

  5. Disciplined capital allocation and efficient trial execution (Mar 2026 quarterly).

Initiatives in the last 24 months

InitiativeDateDetailOutcome
Clendon Biotech Capital facilityOct 2024Up to A$38.5M, 15% interest capitalised, options ~19.9% of sharesSucceeded by LFO facility
Expansion of trial scopeLate 2024–2025Lender encouraged larger trial scale to support Phase 3 readinessIncreased cost base
iNGENū CRO appointmentMar 2025Tendered CRO for IRX-211 and IRX-616aStudy orders suspended May/Jun 2026
SRX-25 additionNov 2025Oral esketamine + CYP450 inhibitor for TRDProtocol drafted; unfunded
LFO facility expansionDec 2025+A$12.6M; total ~A$52.3MCancelled 20 May 2026
Rebrand to NexalisFeb 2026Reflects broadened modality focusCompleted
Point8 Capital facilityMay 2026Binding LOI for up to A$53M in three sub-facilities, 15% interest, general security deedCeased 6 Jul 2026
Cost-saving program2,026Product development activities ceased; discretionary spend reducedOngoing
Revised clinical development planJul 2026 onwardReprioritisation across three assets; IRX-211 recruitment review; IRX-616a Phase 2 designUnder way

ESG/sustainability commitments: none disclosed.

Medium-term targets / guidance

No financial guidance has been issued. Earlier operational targets (e.g., IRX-211 first patient first dose in Q3 2025; SRX-25 first patient screened Q4 2025) were missed or superseded. As of October 2026 the company states it has no meaningful funding discussions under way.

Products & Services

Current development pipeline

IRX-211 (Breakthrough Cancer Pain)

  • Description: Drug-device combination delivering a fixed dose of dronabinol (synthetic THC) via pressurised metered-dose inhaler (pMDI), designed for rapid onset and offset analgesia during acute pain flares.

  • Target customer: Opioid-tolerant cancer patients with BTcP, positioned as an alternative to rapid-onset fentanyl products that carry dependency risk.

  • Development: Phase 1 single-ascending-dose study (four cohorts of eight healthy volunteers) completed 2023; final CSR 2024 confirmed safety and identified Phase 2 dose (1H2024 report). Phase 2 is a multicentre, randomised, double-blind, placebo-controlled crossover study with individual dose titration targeting 156 participants (ASX 20 Apr 2026; 1H2026 report). Lead site Vitalis (Melbourne); GenesisCare sites budget agreed Dec 2025.

  • Regulatory: 505(b)(2) pathway; company expects three-year data exclusivity on approval (Stockhead interview).

  • Pricing: Not disclosed.

IRX-616a (Panic Disorder)

  • Description: Inhaled cannabidiol formulation in a pMDI for rapid systemic absorption to treat acute panic and anxiety episodes.

  • Development: Phase 1 randomised, double-blind, placebo-controlled study in up to 24 healthy volunteers at CMAX Adelaide; cohort 1 (8 subjects) completed by 17 Apr 2026; SRC approved cohort 3 on 28 Apr 2026; completed during 1H2026 with no serious adverse events (ASX 6 Jul 2026).

  • Market gap claim: Company states there is no FDA-approved inhaled drug for panic disorder.

  • Pricing: Not disclosed.

SRX-25 (Treatment-Resistant Depression)

  • Description: Oral fixed-dose combination of esketamine with a CYP450 inhibitor intended to reduce first-pass metabolism and improve systemic exposure, enabling oral, potentially home-based dosing versus J&J's clinic-supervised intranasal Spravato (ASX 26 Nov and 4 Dec 2025).

  • Development: Phase 1 protocol and Investigator's Brochure drafted (Q1 2026); IP strategy progressed; Phase 1 planned for Australia once funded (1H2026 report).

  • Pricing: Not disclosed.

Discontinued / legacy products

ProductEraDescriptionStatus
Medihale inhaler and pods2020–2022Sealed, tamper-resistant pod vaporiser for medical cannabis c-liquids (heat-not-burn); pods filled with EC Pharma formulations (e.g., 275mg CBD/275mg THC); prescribed via TGA SASGenerated A$167,301 revenue FY2021; de-emphasised as company moved to registrable drugs
BodyTel system2016–2020Chronic-disease and remote-monitoring telehealth platform (glucose, blood pressure, etc.)Legacy; disposal details not disclosed in reviewed sources
Omnitest 5 BT (with B. Braun)2,018Bluetooth glucose meter integrated with Body-TelLegacy partnership
FeverTel2,020Temperature-monitoring extension of BodyTel during COVID-19Legacy
Coagulation home monitoring2,017Announced market entryLegacy
IRX211 for CRPS2022–2023Original lead indicationReplaced by BTcP (Jan 2024)

Financial Narrative

Data provenance: FY2021–FY2023 from annual reports as reported by StockAnalysis/TipRanks/Kalkine and cross-checked against FY2022 Annual Report and FY2024 4E comparatives; FY2024 from FY2024 Annual Report/FY2025 4E comparatives; FY2025 from unaudited Appendix 4E (27 Feb 2026) unless marked audited (derived from 1H2026 comparatives).

Income statement

Notes:

  • FY2022 revenue conflicts across aggregators (A$24.8k TipRanks; A$0.02M StockAnalysis; A$52k Stockopedia). A$25k used.

  • FY2021–FY2023 EPS computed from net loss / weighted shares (167.57M, 173.05M, 189.38M per TipRanks); FY2024–FY2025 EPS as reported.

  • FY2024 EBITDA approximated as pre-tax loss less finance costs (aggregators conflict); FY2025 EBITDA approximated similarly from 4E.

  • Margins: gross, operating, EBITDA and net margins are not meaningful given nil customer revenue from FY2023. FY2021 net margin on sales was approx. -664%.

  • Revenue CAGR FY2021–FY2025: not meaningful (revenue fell to zero).

Balance sheet

Notes: FY2025 total assets, equity and working capital shown on the audited basis (1H2026 comparatives: total assets A$1,432,620; equity -A$950,524). Unaudited 4E showed total assets A$1,208,144 and equity -A$1,175,000. FY2021–FY2022 debt assumed nil (no borrowings evident; convertible notes first appear in FY2024 cash flows). Blank cells = not publicly disclosed in reviewed sources.

30 June 2026 snapshot (Half-Year Report): cash A$791,334; receivables A$729,537 (R&D rebate A$630,103); total assets A$1,625,036; trade and other payables A$2,762,512 (of which A$2,125,952 owed to related party iNGENū); borrowings A$720,084 (LFO facility A$641,848, insurance funding A$78,236); total liabilities A$3,489,218; net liabilities A$1,864,182; current liabilities exceed current assets by A$1,875,337.

Cash flow: notes and sources

Notes: FY2021–FY2023 operating and financing flows per Kalkine aggregation (FY2021–FY2022 operating cash flow inferred from free cash flow, capex nil). FY2025 financing comprised A$535k share proceeds, A$1,022k borrowings, less A$369k repayments and A$58k costs.

Commentary

The five-year record is that of a shell in transition rather than an operating business. FY2021 was the last year with product revenue (Medihale), and the A$2.8M cash balance at end-FY2021 was the high-water mark following the 2020 Cannvalate and MDI placements. From FY2022 the company redirected spend to clinical development; R&D expense rose to A$0.98M in FY2022 and A$1.45M in FY2023 as the IRX211 Phase 1 ran, cash fell to A$0.72M by end-FY2023, and FY2024 was a holding year (R&D just A$0.62M) while the company negotiated the Clendon facility. FY2025 saw R&D nearly triple to A$1.76M as Phase 2 and Phase 1 trial drug manufacturing proceeded, financed by a mix of the lender facility, R&D financing and a small equity raise.

The key inflection is the balance sheet: equity turned negative in FY2024 (-A$64k) and deteriorated to -A$951k (audited) at end-FY2025 and -A$1.86M at 30 June 2026, primarily because trial costs were being incurred on credit from the related-party CRO (trade payables up from A$568k at end-FY2024 to A$2.44M at 30 June 2026) in anticipation of lender drawdowns that never arrived. Of A$2.4M in drawdown requests submitted to LFO, only A$0.8M was received before cancellation. The R&D Tax Incentive (43.5% refundable offset for small entities) is now the company's most reliable inflow and is explicitly a key input to the going-concern forecast.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

Segment metricFY2023FY2024FY2025

Single segment revenue from customers (AUD K)

000

Single segment other income incl. R&D rebate (AUD K)

1,200560768

Single segment pre-tax loss (AUD K)

-1,443-1,209-1,829

Capital Programmes

ProgramModalityIndicationStage (Oct 2026)Status

IRX-211

Inhaled dronabinol (synthetic THC), pMDI

Breakthrough cancer pain

Phase 2 (first patient screened Apr 2026)

Study order with iNGENū suspended; recruitment review under way

IRX-616a

Inhaled cannabidiol (CBD), pMDI

Panic disorder

Phase 1 complete (healthy volunteers)

Database lock and CSR delayed; Phase 2 design in progress

SRX-25

Oral esketamine + CYP450 inhibitor, fixed-dose

Treatment-resistant depression

Pre-clinical / Phase 1 protocol drafted

Awaiting funding

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue from customers (AUD K)

16725000

Other income incl. R&D rebate (AUD K)

001,200560768

Product development / R&D expense (AUD K)

1209801,4506221,760

SG&A and corporate expenses (AUD K)

9908901,0801,020670

Operating income (AUD K)

-1,110-1,950-1,420-1,280-1,490

EBITDA (AUD K)

-1,120-1,940-1,410-1,200-1,690

Finance costs (AUD K)

001088136

Pre-tax income (AUD K)

-1,111-1,927-1,443-1,209-1,829

Net income (AUD K)

-1,111-1,927-1,443-1,209-1,829

Basic EPS (A$ cents)

-0.66-1.11-0.76-0.567-0.848

Diluted EPS (A$ cents)

-0.66-1.11-0.76-0.567-0.848

Dividends per share (A$ cents)

00000

Income Statement (AUD) and Per-Share Data

Metric (AUD)1H20251H2026Change

Other income (R&D rebate)

551,449630,103+14.3%

Product development expenditure

1,006,1141,275,757+26.8%

Directors' fees

1,270108,988—

Finance costs

55,115121,543+120.5%

Net loss

854,3321,297,938+51.9%

Basic EPS (cents)

-0.40-0.52—

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Cash and equivalents (AUD K)

2,8032,133716195437

Total assets (AUD K)

———7121,433

Total liabilities (AUD K)

———7762,383

Short-term debt (AUD K)

———34426

Long-term debt (AUD K)

———0315

Total debt (AUD K)

———34741

Net debt (AUD K)

-2,803-2,133-716-161304

Total equity (AUD K)

——665-64-951

Goodwill and intangibles (AUD K)

——000

Working capital (AUD K)

———-64-634

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (AUD K)

-1,174-1,846-1,962-369-888

Capex (AUD K)

00000

Free cash flow (AUD K)

-1,174-1,846-1,962-369-888

Financing cash flow (AUD K)

2,2581,176544-1521,130

Dividends paid (AUD K)

00000

Buybacks (AUD K)

00000

R&D tax offset received (AUD K)

———763490

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY20251H2026

ROE

—

n.m. (negative equity)

——

ROA (net loss / total assets)

—-170%

-113% (audited basis)

n.m. (half-year)

Current ratio

—0.92x0.69x0.46x

Asset turnover

0000

“—” = not publicly disclosed.

Results by Region

RegionFY2023FY2024FY2025

Australia revenue from customers (AUD K)

000

Rest of world revenue from customers (AUD K)

000

Australia R&D rebate income (AUD K)

1,200402762

Share Price

Metric202120252026

Reference share price (AUD)

0.0950.0250.011

Performance Details

PerformanceValueSource

1-year (relative to ASX 200)

-78.5%

Market Index

~1-year absolute (from ~A$0.036 on 26 Nov 2025 to ~A$0.011)

approx. -70%

InvestSMART price at release

~5-year absolute (A$0.095 Oct 2021 to ~A$0.011)

approx. -88%

Computed

Long-run (from A$0.31–0.33 in early 2017)

approx. -97%

Computed from InvestSMART release prices

52-week range

approx. A$0.009 – A$0.036

InvestSMART / Kalkine

ASX rank by market cap

2,288 of 2,337

Market Index

Valuation Snapshot

MultipleValue

P/E

n.m. (loss-making)

EV/Sales

n.m. (MarketScreener shows ~6x on R&D rebate "sales"; not meaningful)

P/B

n.m. (negative book value)

Approx. EV

Market cap ~A$2.7M + borrowings A$0.08M (post-settlement) - cash A$0.79M ≈ A$2.0M, excluding A$2.76M trade payables

Analyst Conclusions

Management guidance

No financial guidance. Management states its focus is identifying funding options, establishing clinical development priorities and planning capital-efficient execution (Jun-26 quarterly), while seeking deferral of most of the A$2.13M owed to iNGENū until a significant capital raise or new funding partner is secured. Consensus growth expectations: none (no coverage).

Bull case

  1. Optionality at a near-zero valuation: Two Phase 1-complete inhaled assets and an esketamine program trade at an EV of roughly A$2M; any licence or funding partner could re-rate the stock several-fold.

  2. IRX-616a de-risked on safety: Clean Phase 1 with dose-ranging insights in an indication without an approved inhaled therapy makes it the most partnerable asset.

  3. Clean-up of liabilities: The LFO settlement removed secured debt and 38.4M options; the R&D rebate (A$630k receivable) provides near-term cash.

Bear case

  1. Funding cliff: Two consecutive facility failures and no active negotiations, with liabilities exceeding A$3.4M against under A$0.8M cash at 30 June 2026.

  2. Execution doubts: IRX-211 Phase 2 struggled to recruit even when funded, and the company added a third program it could not finance.

  3. Governance and related-party concentration: The CEO-related CRO is both the main supplier and largest creditor, complicating independent decision-making and any restructuring.

Key catalysts and monitorables (next 12 months)

  • Sep-26 quarterly Appendix 4C (due by 31 Oct 2026): cash balance and any iNGENū deferral agreement.

  • Receipt of the A$630k R&D rebate receivable.

  • Any new funding facility, equity raise, partnering or asset sale announcement.

  • Completion of IRX-616a database lock and Clinical Study Report.

  • Outcome of IRX-211 Phase 2 recruitment review and revised clinical plan.

  • FY2026 audited accounts (Feb–Mar 2027) and going-concern opinion.

  • Board strengthening (independent directors) and any ASX queries on financial condition.

Analyst verdict

Lifespot Health has undergone two complete reinventions since listing in 2017: from remote health monitoring (BodyTel) to medicinal cannabis devices (Medihale), and then to regulated drug development as InhaleRx and now Nexalis Therapeutics. The current strategy is intellectually coherent. Reformulating known actives such as dronabinol, CBD and esketamine for faster onset or better access, and seeking FDA approval through the 505(b)(2) pathway, is a recognised, capital-efficient biotech playbook. Clinically, the company has delivered: two Phase 1 studies completed without serious safety signals, and a Phase 2 trial initiated.

Financially, however, the business is in survival mode. The model depended entirely on a single lender advancing clinical funding against invoices; when Linlithgow cancelled in May 2026 after funding only A$0.8M of A$2.4M requested, and Point8's replacement collapsed in July, the company was left with suspended trials, net liabilities of A$1.86M, and A$2.13M owed to a CRO related to its own CEO. Its auditor has flagged material going-concern uncertainty, and management has acknowledged that no meaningful funding talks are under way. At roughly A$0.011 per share and a market capitalisation near A$3M, the equity is priced as an option on a rescue transaction rather than on the science.

Our assessment is that the probability-weighted outcome is dominated by recapitalisation terms: a successful partnering of IRX-616a or a deeply discounted raise could preserve the assets, but existing shareholders should expect heavy dilution in nearly every survival scenario, and a creditor-driven restructuring cannot be excluded. Governance improvements, in particular independent board additions and an arm's-length resolution of the iNGENū exposure, are prerequisites for institutional capital. Until funding is secured, the stock is suitable only for speculative, loss-tolerant capital, and the key near-term test is the September-quarter cash report and any announced funding solution.


All items marked "not publicly disclosed" should be verified against the 2025 Annual Report lodged 31 March 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground (public)Independence

Sean Williams

Non-Executive Chairman

Oct 2021

Appointed chair at the InhaleRx rebrand; fees taken in share rights (Jul 2026)

Treated as independent NED (not formally confirmed in reviewed sources)

Darryl Davies

CEO and Executive Director

CEO since 27 Sep 2022; Director since 25 Jun 2026

B.Sc.; related to iNGENū CRO Pty Ltd, the company's principal CRO and largest creditor

Not independent

James Barrie

Non-Executive Director and Company Secretary

Director since 12 May 2026

CPA; long-standing company secretary; received A$7,500 for secretarial services in 1H2026

Not independent (executive service provider)

Executive Leadership Team

NameTitleTenure

Darryl Davies

Chief Executive Officer

Since Sep 2022

Dr Robert (Rob) Jenny, B.A., B.Sc., Ph.D.

Chief Scientific / Technology Officer

Since Sep 2022

Greg Hammond

Chief Financial Officer

—

James Barrie, CPA

Company Secretary

Multi-year

“—” = not publicly disclosed.

Directors' Remuneration

ItemAmount (AUD)Source

Shares issued to settle CEO fees, Oct 2025

149,850 (4,499,914 shares at A$0.0333)

FY2025 4E Note 7

Shares issued to settle CEO fees, Oct 2024

99,900 (3,444,828 shares)

FY2025 4E Note 7

Shares issued to settle directors' fees, Dec 2024

75,890

FY2025 4E Note 7

Directors' fees expense FY2025 (cash, prelim)

1,270

FY2025 4E

Directors' fees expense 1H2026

108,988

1H2026 report

Fees payable to KMP at 30 Jun 2026

194,789

1H2026 Note 11

Performance/share rights to current and former directors, 14 Jul 2026

4,120,019 rights

1H2026 Note 12

Major Shareholders

HolderStakeDate / source

Citicorp Nominees Pty Ltd

1.70% (3,623,477 shares)

Market Index (date of compilation unclear)

HSBC Custody Nominees (Australia)

1.31% (2,799,928 shares)

Market Index

Cannvalate Pty Ltd (historic)

17.92% (30.2M shares)

Mar 2021

M I D Wealth Pty Ltd (historic)

7.78% (13.1M shares)

Mar 2021

Pyxis Holdings Pty Ltd (historic)

5.29%

Mar 2021

Unnamed substantial holder change

—

ASX notice 30 Jul 2026

“—” = not publicly disclosed.

Competitive Landscape

Competitors by Segment

ProgramCompetitor / productCompanyTypePositioning vs Nexalis

IRX-211 (BTcP)

Fentanyl buccal tablet (Fentora)

Teva

Approved

Entrenched rapid-onset opioid standard; dependency/abuse concerns are Nexalis' wedge

IRX-211

Fentanyl sublingual (Abstral)

Various licensees

Approved

Same

IRX-211

Intranasal fentanyl (Instanyl / PecFent)

Various

Approved

Fastest-onset opioid alternative

IRX-211

Oral dronabinol (Marinol, Syndros)

Various

Approved (other indications)

Same molecule, slow oral onset; provides 505(b)(2) reference safety data

IRX-616a (PD)

Benzodiazepines (alprazolam, clonazepam)

Pfizer/Viatris, generics

Approved

Cheap generic standard; dependency concerns

IRX-616a

SSRIs/SNRIs

Generics

Approved

Maintenance therapy, slow onset; not acute

IRX-616a

Epidiolex (oral CBD)

Jazz Pharmaceuticals

Approved (epilepsy)

Oral CBD reference; not indicated for PD

SRX-25 (TRD)

Spravato (intranasal esketamine)

Johnson & Johnson

Approved

Market leader; requires supervised clinic dosing (Nexalis' wedge)

SRX-25

Auvelity (dextromethorphan-bupropion)

Axsome

Approved (MDD)

Oral NMDA-modulating competitor

SRX-25

Psilocybin (COMP360)

Compass Pathways

Phase 3

Novel TRD entrant

SRX-25

GH001 (inhaled mebufotenin)

GH Research

Clinical

Inhaled rapid-acting TRD candidate

ASX cannabinoid/mental-health peers

Zelira Therapeutics, Emyria, Bod Science, Avecho Biotechnology, Incannex Healthcare (now Nasdaq)

Various

Clinical/commercial

Compete for the same small-cap investor pool and partners

Peer Comparison FY2025

MetricNexalis (FY2025)J&J Spravato franchiseASX cannabinoid peers

Revenue

A$0

Approx. US$1.1bn (J&J FY2024 reporting; verify)

Mostly sub-A$5M; not compiled

Revenue growth

—

Strong double-digit (verify)

Not compiled

Net margin

—

Not disclosed at product level

Mostly loss-making

R&D intensity

n.m. (R&D approx. 71% of opex)

—

Not compiled

Company Snapshot

2016

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Clean Phase 1 safety data on two assets: IRX211 Phase 1 (four cohorts) completed with CSR confirming safety (FY2024 Annual Report); IRX-616a Phase 1 completed with no serious adverse events (ASX 6 Jul 2026).
  • Phase 2-ready lead asset: IRX-211 Phase 2 is HREC-approved and screened its first patient on 20 Apr 2026.
  • Regulatory efficiency: All three programs use the 505(b)(2) pathway, leveraging existing safety data for dronabinol, CBD and esketamine.
  • Trial drug already manufactured: Manufacturing of IRX-211 and IRX-616a trial drugs was completed in Q4 2025 (Dec-25 quarterly), a sunk cost that reduces restart costs.
  • Reliable non-dilutive inflow: R&D Tax Incentive receipts of A$898,719 in 1H2026 and a further A$630,103 receivable at 30 June 2026.
  • Secured debt extinguished: The 27 Aug 2026 settlement removed the A$641,848 LFO liability and 38.4M lender options, cleaning up the cap table.

Weaknesses

  • Net liabilities of A$1.86M at 30 June 2026 and current-liability deficit of A$1.88M (1H2026 report).
  • Auditor going-concern emphasis (RSM review report, 1 Sep 2026).
  • Concentrated, related-party creditor: A$2,125,952 owed to iNGENū, an entity related to the CEO (Note 11).
  • Poor Phase 2 recruitment at the lead site, prompting a formal review (1H2026 report).
  • Board depth: Three directors, majority non-independent, 0% female; two NED resignations in May–June 2026.
  • Disclosure quality lapse: Half-year report had to be re-lodged on 1 Sep 2026 to remove draft wording; FY2025 unaudited vs audited loss differed by approx. A$210k.

Opportunities

  • Partnering a Phase 1-complete inhaled CBD asset in an indication the company says has no FDA-approved inhaled therapy.
  • TRD access gap: SRX-25 targets home dosing versus clinic-supervised Spravato, a franchise exceeding US$1bn in annual sales (J&J reporting).
  • Non-opioid BTcP positioning in a cancer pain market the company sizes at approx. US$11bn by 2028.
  • Recapitalisation at a low base: Market cap of approx. A$3M means any funding deal or licence could be highly accretive.
  • R&D rebate leverage: 43.5% refundable offset reduces net cost of restarting trials in Australia.
  • Asset sale or merger with a better-funded biotech seeking clinical-stage assets.

Threats

  • Insolvency risk: Company states there are no meaningful funding discussions under way (1H2026 report).
  • CRO creditor action if the deferral agreement with iNGENū is not reached.
  • Severe dilution from any rescue raise at sub-A$0.01 prices.
  • Competitive advances in TRD (psychedelics, Auvelity) and pain (non-opioid analgesics) eroding the value proposition.
  • ASX compliance risk (continuous disclosure, financial condition under Listing Rule 12.2) given negative equity.
  • Key-person and related-party risk concentrated in the CEO.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Initial A$247.5k drawdown under Clendon facility; IRX-211 trial drug manufacturing commencesFirst funding under lender model
2025 (Q2–Q3)IRX-211 Phase 2 HREC approval; Phase 1 CSR complete; PCT application filedAsset de-risking
2 Oct 20254.5M shares issued to settle CEO fees (A$149,850)Cash preservation, dilution
31 Oct 2025LFO debt facility agreement executedFunding continuity
26 Nov 2025SRX-25 added; A$750k placement and rights issue announced; rebrand flagged; shares fall ~22%Strategic broadening, market scepticism
4 Dec 2025LFO +A$12.6M for SRX-25; total ~A$52.3MHeadline funding peak
9 Dec 202517.1M placement shares issued at A$0.025 (A$427.5k)Working capital
10 Dec 2025Company overview presentationInvestor marketing
23 Dec 20254.31M entitlement shares (A$107,730)Small take-up of rights issue
9 Jan 2026Final 6.9M Tranche 1 shares (A$172.5k)Placement Tranche 1 complete (A$600k)
29 Jan 2026Dec-25 quarterly: trial drugs manufactured; CTRAs executed; IRX-211 screening delaysExecution progress with delays
29 Jan 2026General Meeting approves name change and Tranche 2Corporate
12 Feb 20262026 Clinical Development Outlook webinar and slidesGuidance on milestones
17 Feb 2026Trading as Nexalis Therapeutics (NX1); Tranche 2 (6M shares) and LFO options (10.9M) issuedRebrand complete
27 Feb 2026FY2025 preliminary results: loss A$1.83M (unaudited)Results
31 Mar 20262025 Annual Report lodged (audited loss approx. A$1.62M)Audit adjustments upward to rebrate
17 Apr 2026IRX-616a Phase 1 cohort 1 complete; cohort 2 dosing beginsClinical progress
20 Apr 2026First patient screened in IRX-211 Phase 2Key milestone
28 Apr 2026SRC approves IRX-616a cohort 3Clinical progress
30 Apr 2026Mar-26 quarterly and 4C: cash A$511k; operating outflow A$474kThin runway
12–13 May 2026Dr Ronald Wise resigns; James Barrie appointed directorBoard change
20 May 2026LFO cancels remaining commitment (only A$0.8M of A$2.4M requests funded)Critical funding failure
22–26 May 2026Trading halt then voluntary suspensionDisclosure event
28 May 2026Binding LOI with Point8 for up to A$53M; reinstated; shares fall from A$0.025 to ~A$0.009–0.011Market loses confidence
29 May 2026AGM; all resolutions incl. director share rights approvedGovernance
25 Jun 2026Darryl Davies joins board; Tony Fitzgerald resignsBoard reduced to three
Jun 2026iNGENū study orders suspended for IRX-211 and IRX-616aClinical work halted
6 Jul 2026Point8 talks cease; IRX-616a Phase 1 completed with no SAEs; A$490k RDTI receivedMixed: clinical success, financing failure
14 Jul 20264.12M share rights issued in lieu of director feesDilution
30–31 Jul 2026Substantial holder change; Jun-26 quarterly and 4COngoing disclosure
27 Aug 2026LFO settlement deed: A$641,848 debt and 38.4M options extinguished for 15M options at A$0.15Removes secured debt
31 Aug – 1 Sep 2026Half-year report (loss A$1.30M; net liabilities A$1.86M; going-concern uncertainty); corrected to remove draft wordingDisclosure quality issue

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue from customers fell from AUD 0.2 Mn in FY2021 to AUD 0 Mn in FY2025.
Nexalis Therapeutics Ltd — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue from customers0.20000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.